TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

被引：0

作者：

D. Ferraro

D. Goldstein

R. L. O’Connell

J. R. Zalcberg

K. M. Sjoquist

N. C. Tebbutt

P. Grimison

S. McLachlan

L. L. Lipton

P. Vasey

V. J. Gebski

C. Aiken

M. Cronk

S. Ng

C. S. Karapetis

J. Shannon

机构：

[1] University of Sydney,National Health and Medical Research Council Clinical Trials Centre

[2] University of New South Wales,Prince of Wales Clinical School

[3] Monash University,Department of Epidemiology and Preventive Medicine

[4] Austin Health,Haematology and Oncology Clinics of Australasia

[5] Chris O’Brien Lifehouse,Department of Medical Oncology

[6] St Vincents Hospital,Department of Pathology

[7] University of Melbourne,undefined

[8] Western Health,undefined

[9] Wesley Medical Centre,undefined

[10] Nambour General Hospital,undefined

[11] Flinders University,undefined

[12] Nepean Cancer Care Centre,undefined

[13] University of Melbourne,undefined

[14] Sir Charles Gairdner Hospital,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2016年 / 78卷

关键词：

Biliary tract cancer; KRAS; Panitumumab; Chemotherapy; Phase II trial; Cancer antigen 19.9;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：361 / 367

页数：6

共 50 条

[31] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Lan, Chunyan
Shen, Jingxian
Wang, Yin
Li, Jundong
Liu, Zhimin
He, Mian
Cao, Xinping
Ling, Jiayu
Huang, Jiaming
Zheng, Min
Zou, Guorong
Yan, Haowen
Liu, Qing
Yang, Fan
Wei, Wei
Deng, Yanhong
Xiong, Ying
Huang, Xin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
[32] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
Xu, Xiaoting
Huan, Jian
Miao, Hui
Wang, Hao
Wang, Yue
Zhu, Hongyu
Jiang, Jun
Zhou, Juying
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
[33] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Kjetil Boye
Alessandra Longhi
Tormod Guren
Susanne Lorenz
Stine Næss
Michela Pierini
Ingeborg Taksdal
Ingvild Lobmaier
Marilena Cesari
Anna Paioli
Ayca M. Løndalen
Elisabetta Setola
Ivar Hompland
Leonardo A. Meza-Zepeda
Kirsten Sundby Hall
Emanuela Palmerini
Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
[34] Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Brastianos, Priscilla K.
Lee, Eudocia Quant
Cohen, Justine V.
Tolaney, Sara M.
Lin, Nancy U.
Wang, Nancy
Chukwueke, Ugonma
White, Michael D.
Nayyar, Naema
Kim, Albert
Alvarez-Breckenridge, Christopher
Krop, Ian
Mahar, Maura Keeley
Bertalan, Mia S.
Shaw, Brian
Mora, Joana L.
Goss, Nathaniel
Subramanian, Megha
Nayak, Lakshmi
Dietrich, Jorg
Forst, Deborah A.
Nahed, Brian V.
Batchelor, Tracy T.
Shih, Helen A.
Gerstner, Elizabeth R.
Moy, Beverly
Lawrence, Donald
Giobbie-Hurder, Anita
Carter, Scott L.
Oh, Kevin
Cahill, Daniel P.
Sullivan, Ryan J.
NATURE MEDICINE, 2020, 26 (08) : 1280 - +
[35] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Boye, Kjetil
Longhi, Alessandra
Guren, Tormod
Lorenz, Susanne
Naess, Stine
Pierini, Michela
Taksdal, Ingeborg
Lobmaier, Ingvild
Cesari, Marilena
Paioli, Anna
Londalen, Ayca M.
Setola, Elisabetta
Hompland, Ivar
Meza-Zepeda, Leonardo A.
Hall, Kirsten Sundby
Palmerini, Emanuela
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
[36] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Chaft, Jamie E.
Oezkan, Filiz
Kris, Mark G.
Bunn, Paul A.
Wistuba, Ignacio I.
Kwiatkowski, David J.
Owen, Dwight H.
Tang, Yan
Johnson, Bruce E.
Lee, Jay M.
Lozanski, Gerard
Pietrzak, Maciej
Seweryn, Michal
Byun, Woo Yul
Schulze, Katja
Nicholas, Alan
Johnson, Ann
Grindheim, Jessica
Hilz, Stephanie
Shames, David S.
Rivard, Chris
Toloza, Eric
Haura, Eric B.
McNamee, Ciaran J.
Patterson, G. Alexander
Waqar, Saiama N.
Rusch, Valerie W.
Carbone, David P.
NATURE MEDICINE, 2022, 28 (10) : 2155 - +
[37] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
Lan, Chunyan
Huang, Xin
Shen, Jing-Xian
Wang, Yin
Xiong, Ying
Li, Jundong
Cao, Xinping
Deng, Yanhong
He, Mian
Zou, Guorong
Wang, Xiaodi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[38] AFATINIB COMBINED WITH GEMCITABINE/CISPLATIN IN CHEMOTHERAPY NAIVE PATIENTS WITH ADVANCED BILIARY TRACT CANCER: RESULTS AND TRANSLATIONAL ANALYSIS OF AN OPEN-LABEL, PHASE I TRIAL
Thomaidis, Thomas
Maderer, Annett
Schad, Arno
Ruckes, Christian
Weinmann, Arndt
Sivanathan, Visvakanth
Marquardt, Jens U.
Foerster, Friedrich
Galle, Peter R.
Woerns, Marcus
Moehler, Markus
GASTROENTEROLOGY, 2019, 156 (06) : S1047 - S1047
[39] Safety and efficacy of Afatinib with Gemcitabine/Cisplatin in chemo-naive patients with metastatic biliary tract cancer: An open-label, uncontrolled phase Ib trial
Moehler, M.
Ehrlich, A.
Ruckes, C.
Thomaidis, T.
Weinmann, A.
Galle, P. R.
Woerns, M. A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S440 - S440
[40] Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
Schwartzberg, Lee
Hermann, Robert
Flinn, Ian
Flora, Douglas
Hsi, Eric D.
Hamid, Oday
Shi, Peipei
Lin, Boris K.
Myrand, Scott P.
Nguyen, Tuan S.
Dreyling, Martin
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 91 - 97

← 1 2 3 4 5 →